Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors

Phase 1

Terminated

• Conditions: Advanced Solid Tumor, Adult
• Interventions: Drug: RP-3500 (camonsertib)

• Registration Number: NCT04972110
• Lead Sponsor: Repare Therapeutics

Brief Summary

The primary purpose of this study is to assess the safety and tolerability of niraparib or olaparib in combination with RP-3500 (camonsertib), in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) of RP-3500 (camonsertib) in combination with niraparib or olaparib, examine pharmacokinetics (PK) and assess anti-tumor activity.

Detailed Description

This is a first-in-human Phase 1b/2, multi-center, open-label, dose-escalation and expansion study to:

* Evaluate the safety profile and MTD of RP-3500 (camonsertib) when administered orally in combination with niraparib or olaparib to establish the recommended Phase 2 dose and schedule.

* Characterize the PK profile of RP-3500 (camonsertib) in combination with niraparib or olaparib

* Assess anti-tumor activity associated with RP-3500 (camonsertib) in combination with niraparib or olaparib

* Examine biomarker responses and establish a correlation with RP-3500 (camonsertib) treatment in combination with niraparib or olaparib.

After the RP2D and schedule is determined, expansion cohort(s) for RP-3500 (camonsertib) in combination with niraparib or olaparib will be enrolled to study the anti-tumor effect, and further examine the safety, PK, and pharmacodynamic (PD).

Sponsor decided to terminate study early therefore, the Phase 2 expansion was not conducted

Study Timeline

• Study First Submitted: 2021-07-02
• Study First Submitted QC: 2021-07-16
• Study Start: 2021-07-21
• Study First Posted: 2021-07-22
• Primary Completion: 2024-11-13
• Study Completion: 2024-11-13
• Results First Submitted: 2025-05-29
• Status Verified: 2025-10
• Results First Submitted QC: 2025-10-01
• Last Update Submitted: 2025-10-01
• Results First Posted: 2025-10-30
• Last Update Posted: 2025-10-30

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 156

Inclusion Criteria

• Male or female and ≥18 years-of-age at the time of signature of the informed consent
• Confirmed advanced solid tumors resistant or refractory to standard treatment
• Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
• Evaluable disease as per RECIST v1.1
• Next generation sequencing (NGS) report obtained in CLIA-certified or equivalent laboratory demonstrating eligible tumor biomarkers.
• Submission of available tumor tissue or willingness to have a biopsy performed if safe and feasible
• Acceptable hematologic and organ function at screening
• Negative pregnancy test for women of childbearing potential at Screening and prior to first study drug.
• Ability to swallow and retain oral medications.

Exclusion Criteria

• Prior therapy with an ATR or DNA-dependent protein kinase (DNA-PK) inhibitor.
• Chemotherapy, small molecule anticancer or biologic anticancer therapy given within 10 days or 5 half-lives (whichever is longer), prior to first dose of study drug.
• Use of radiotherapy (except for palliative reasons) within 7 days prior to first dose of study drug.
• History or current condition, therapy, or laboratory abnormality that might confound the study results, or interfere with the patient's participation for the full duration of the study treatment.
• No other anticancer therapy is to be permitted while the patient is receiving study treatment.
• Major surgery ≤28 days or minor surgical procedures ≤7 days prior to first study treatment dose.
• Uncontrolled, symptomatic brain metastases.
• Uncontrolled high blood pressure
• History of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) diagnosis
• Presence of other known active invasive cancers.
• Pregnant or breastfeeding women.
• Psychological, familial, sociological, or geographical conditions that do not permit compliance with the study protocol and/or follow-up procedures outlined in the protocol.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Phase Ib Dose Escalation	RP-3500 (camonsertib)	Multiple dose levels of RP-3500 (camonsertib) for oral administration in combination with niraparib and/or Multiple dose levels of RP-3500 (camonsertib) for oral administration in combination with olaparib
Phase 2 Expansion Cohorts	RP-3500 (camonsertib)	Expansion cohort with RP-3500 (camonsertib) + niraparib and/or Expansion cohort RP-3500 (camonsertib) + olaparib

Primary Outcome Measures

Name	Time	Method
Determine the Safety and Tolerability of Niraparib or Olaparib in Combination With RP-3500 in Patients With Molecularly Selected Solid Tumors	Start of treatment to 30 days post last dose, up to 23.7 months	Treatment Related Treatment-Emergent Adverse Events (TRAE) with ≥3 CTCAE Grade
Define the Recommended Phase 2 Dose (RP2D) of RP-3500 in Combination With Niraparib or Olaparib in Patients With Molecularly Selected Solid Tumors	During 21 days (one cycle) from the initiation of the study treatment	Frequency of DLTs during the DLT observation period

Trial Locations

Locations (13)

Participating Site #1018; 🇺🇸 Phoenix, Arizona, United States

Participating Site #1025; 🇺🇸 San Francisco, California, United States

Participating Site #1028; 🇺🇸 Aurora, Colorado, United States

Participating Site #1012; 🇺🇸 New Haven, Connecticut, United States

Participating Site #1017; 🇺🇸 Jacksonville, Florida, United States

Participating Site #1009; 🇺🇸 Baltimore, Maryland, United States

Participating Site #1015; 🇺🇸 Ann Arbor, Michigan, United States

Participating Site # 1016; 🇺🇸 Rochester, Minnesota, United States

Participating Site #1026; 🇺🇸 New York, New York, United States

Participating Site # 1008; 🇺🇸 New York, New York, United States

Scroll for more (3 remaining)